Showing 3201-3210 of 7283 results for "".
- Data Show Amgen's Otezla Benefits Patients with Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/data-show-amgens-otezla-benefits-patients-with-mild-to-moderate-psoriasis/2460775/Amgen’s Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) involvement, according to findings from the placebo-controlled, phase 3 ADVANCE trial, presented at the AAD VMX 2021
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- Sonrei Launches Three New Mineral Gel Sunscreenshttps://practicaldermatology.com/news/sonrei-launches-three-new-mineral-gel-sunscreens/2460756/Three new sunscreens are now available from Sonrei. The sunscreen collection now includes Sonrei Clearly Zinq Tinted Mineral Gel Sunscreen SPF 45
- Research Reveals How Skin May Repair Itselfhttps://practicaldermatology.com/news/research-reveals-how-skin-may-repair-itself/2460755/Activation of two transcription factors may enhance a natural process of skin cell division, a desirable outcome in regenerative medicine, according to a study in Nucleic Acid Research. In normal conditions, one in every four cells isolated from the inner layer of the skin
- GEMME Webinar Series to Assess Impact of Essential Mask Wearing on Skinhttps://practicaldermatology.com/news/gemme-webinar-series-to-assess-impact-of-essential-mask-wearing-on-skin/2460754/Assessing the impact of essential mask wearing, the first of a series of four webinars from GEMME (Galderma Excellence Multichannel Medical Education) launches next month. “Under the mask: the consequences of essential mask wearing,” will stream Saturday, May 8, with Drs. Lu
- C-Jun Protein May Play Role in Psoriasis Developmenthttps://practicaldermatology.com/news/c-jun-protein-may-play-role-in-psoriasis-development/2460753/The "c-Jun" protein may play a major role in the development of psoriasis, but inhibiting this protein may alleviate symptoms, new research suggests. c-Jun belongs to a larger family of transcription factors, DNA-binding factors, known as Activator Protein-1 (AP-1). Previ
- Yale Cancer Center Study Highlights Novel Immunotherapy Approach to Fight Melanomahttps://practicaldermatology.com/news/yale-cancer-center-study-shows-novel-immunotherapy-approach-to-fight-melanoma/2460748/A tumor-targeting and cell-penetrating antibody can stimulate an immune response to help treat melanoma, Yale researchers reported at the American Association of Cancer Research (AACR) virtual annual meeting. “Most approaches rely on direct injection into tumors of ribonucleic aci
- DecisionDx-Melanoma Accurately Predicts Patient Outcomes in Cutaneous Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-accurately-predicts-patient-outcomes-in-cutaneous-melanoma/2460746/Castle Biosciences, Inc.’s DecisionDx-Melanoma is a significant, independent predictor of patient outcomes in cutaneous melanoma. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict risk of cutane
- Practical Dermatology Magazine Mourns the Passing of Two Preeminent Dermatologistshttps://practicaldermatology.com/news/practical-dermatology-mourns-the-passing-of-two-preeminent-dermatologists/2460741/By Wendy Lewis It is with great sadness that Practical Dermatology® magazine pays our respects to two very talented and respected dermatologists, Melanie Grossman, MD and Marta Rendon, MD.
- FDA Grants 510(k) Clearance to Chemence Medical’s Exofin Fusion Redesignhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-chemence-medicals-exofin-fusion-redesign/2460736/The U.S. Federal Drug Administration gave its nod to Chemence Medical’s redesigned exofin fusion skin closure system. Exofin fusion combines a self-adhering flexible mesh strip and a fast-curing 2-octyl cyanoacrylate topical adhesive to close and seal incisions while forming an im